Ulinastatin and thymosin as immune modulators for the treatment of sepsis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Luo, Peng F ^a   Ren, Yu ^a   Liu, Ya Lin ^b   Xia, Zhao Fan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Local Government Office for Public Health   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW;

EID: 84901450335     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009940.pub2     Document Type: Review

References (61)

1. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al.Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273(12):934-41. [PUBMED: 7884952].
2. Adrie C, Alberti C, Chaix-Couturier C, Azoulay E, De Lassence A, Cohen Y, et al.Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. Journal of Critical Care 2005;20(1):46-58. [PUBMED: 16015516].
3. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD001090].
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR, et al.Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 2001;29(7):1303-10. [PUBMED: 11445675].
5. Angus DC. The search for effective therapy for sepsis: back to the drawing board?. JAMA 2011;306(23):2614-5. [PUBMED: 22187284].
6. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001;15(2):101-5. [PUBMED: 11220636].
7. Badamchian M, Fagarasan MO, Danner RL, Suffredini AF, Damavandy H, Goldstein AL. Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. International Immunopharmacology 2003;3(8):1225-33. [PUBMED: 12860178].
8. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mechanisms of Ageing and Development 1997;94(1-3):85-101. [PUBMED: 9147362].
9. Baumann CA, Bedamchian M, Goldstein AL. Thymosin alpha 1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. International Journal of Immunopharmacology 2000;22(12):1057-66. [PUBMED: 11137612].
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al.Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine 2001;344(10):699-709. [PUBMED: 11236773].
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55. [PUBMED: 1303622].
12. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al.Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306(23):2594-605. [PUBMED: 22187279].
13. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Alimentary Pharmacology & Therapeutics 2001;15(12):1899-905. [PUBMED: 11736720].
14. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998;27(5):1383-7. [PUBMED: 9581695].
15. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine 2004;32(3):858-73. [PUBMED: 15090974].
16. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al.Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008;36(1):296-327. [PUBMED: 18158437].
17. Diao Group (Di Ao Ji Tuan). Instruction of Thymosin α1 for Injection [Mai Pu Xin (Zhu She Yong Xiong Xian Tai α1) Shuo Ming Shu]. www.diao.com/products/006.asp (accessed 4 Nov 2012).
18. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Critical Care Medicine 2007;35(5):1244-50. [PUBMED: 17414736].
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563].
20. Enghild JJ, Thøgersen IB, Pizzo SV, Salvesen G. Analysis of inter-alpha-trypsin inhibitor and a novel trypsin inhibitor, pre-alpha-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. The Journal of Biological Chemistry 1989;264(27):15975-81. [PUBMED: 2476436].
21. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al.Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271(23):1836-43. [PUBMED: 8196140].
22. Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties in health and disease. Expert Opinion on Biological Therapy 2004;4(4):559-73. [PUBMED: 15102605].
23. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falc-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians. BMJ 2008;336:995-8. [PUBMED: 18456631].
24. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Critical Care 2006;10(2):R42. [PUBMED: 16542492].
25. Higgins JPT, Altman DG (Editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Hirose J, Ozawa T, Miura T, Isaji M, Nagao Y, Yamashiro K, et al.Human neutrophil 1 elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biological & Pharmaceutical Bulletin 1998;21(7):651. [PUBMED: 9703243].
27. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. The New England Journal of Medicine 2003;348(2):138-50. [PUBMED: 12519925].
28. Huang Y, Chen Z, Zhou C, YaoH, Li M, Xu C. The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-alpha. International Immunopharmacology 2004;4(4):539-46. [PUBMED: 15099531].
29. Inoue K, Takano H, Shimada A, Yanagisawa R, Sakurai M, Yoshino S, et al.Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Molecular Pharmacology 2005;67(3):673-80. [PUBMED: 15576631].
30. Ito K, Mizutani A, Kira S, Mori M, Iwasaka H, Noguchi T. Effect of ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes. Injury 2005;36(3):387-94. [PUBMED: 15710155].
31. Japanese Society of Hospital Pharmacists (Nihon byoin yakuzaishi kai). Pharmaceutical interview form of ulinastatin [Urinasutachin Iyakuhin intabyūfōmu]. www.mochida.co.jp/dis/interview/mcd_n22.pdf April 2011 (accessed 4 Nov 2012).
32. Jones AE, Troyer JL, Kline JA. Cost-effectiveness of an emergency department-based early sepsis resuscitation protocol. Critical Care Medicine 2011;39(6):1306-12. [PUBMED: 21336115].
33. Jönsson-Berling BM, Ohlsson K. Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scandinavian Journal of Clinical and Laboratory Investigation 1991;51(6):549-57. [PUBMED: 1767247].
34. Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettilä V, Finnsepsis Study Group. Long-term outcome and quality-adjusted life years after severe sepsis. Critical Care Medicine 2009;37(4):1268-74. [PUBMED: 19242321].
35. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine 2003;31(4):1250-6. [PUBMED: 12682500].
37. Li CL, Zhang T, Saibara T, Nemoto Y, Ono M, Akisawa N, et al.Thymosin alpha 1 accelerates restoration of T cell-mediated neutralizing antibody response in immunecompromised hosts. International Immunopharmacology 2002;2(1):39-46. [PUBMED: 11789668].
38. Li YM, Chen H, Li X, Zhou W, He MY, Chiriva-Internati M, et al.A new immunomodulatory therapy for severe sepsis: Ulinastatin plus thymosin 1. Journal of Intensive Care Medcine 2009;24(1):47-53. [PUBMED: 19033321].
39. Cooperative Group of immunomodulatory Therapy of Sepsis, Lin HY. Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and maipuxin. Zhonghua Yi Xue Za Zhi 2007;87(7):451-7. [PUBMED: 17459221].
40. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine 2003;348(16):1546-54. [PUBMED: 12700374].
41. Mitka M. Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 2011;306(22):2439-40. [PUBMED: 22166598].
42. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. The New England Journal of Medicine 1999;340(23):1834-5. [PUBMED: 10362831].
43. Mullard A. Drug withdrawal sends critical care specialists back to basics. Lancet 2011;378(9805):1769. [PUBMED: 22106464].
44. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001;16(2):83-96. [PUBMED: 11508871].
45. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
46. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. Journal of Clinical Investigation 2003;112(4):460-7. [PUBMED: 12925683].
47. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al.Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine 2001;345(19):1368-77. [PUBMED: 11794169].
48. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al.Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103(11):4232-9. [PUBMED: 14982877].
49. Russell JA. Management of sepsis. The New England Journal of Medicine 2006;355(16):1699-713. [PUBMED: 17050894].
50. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes. Statistics in Medicine 2008;27(5):746-63. [PUBMED: 17592831].
51. SciClone Pharmaceuticals. Zadaxin Product Monograph. www.sciclone.com/?page_id=900 (accessed 4 Nov 2012).
52. Shikimi T, Handa M. Inhibitory effect of human urinary trypsin inhibitor (urinastatin) on lysosomal thiol proteinases. Japanese Journal Pharmacology 1986;42(4):571-4. [PUBMED: 3543447].
53. Shuangcheng Pharmaceuticals (Shuang Cheng Yao Ye). Instruction of Thymalfasin (Thymosin α1) for Injection [Tai Ji (Zhu She Yong Xiong Xian Fa Xin/ Xiong Xian Tai α1) Shuo Ming Shu]. www.shuangchengmed.com/news_read.php?id=30 June 2006 (accessed 4 Nov 2012).
54. Sosne G, Chan CC, Khroan T, Kennedy M, Szliter EA, Hazlett LD, et al.Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Experimental Eye Research 2001;72(5):605-8. [PUBMED: 11311052].
55. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman HK, Hazlett LD. Thymosin beta4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research 2002;74(2):293-9. [PUBMED: 11950239].
56. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al.Sepsis in European intensive care units: results of the SOAP study. Critical Care Medicine 2006;34(2):344-53. [PUBMED: 16424713].
57. Wang HH, Hu FL, Lin SR, Zhou LY, Qu HT, Yuan AL, et al.The efficacy and safety of domestic ulinastatin in the treatment of acute pancreatitis [Guo Chan Wu Si Ta Ding Zhi Liao Ji Xing Yi Xian Yan De Liao Xiao He An Quan Xing]. Chinese Journal of New Drngs (Zhongguo Xin Yao Za Zhi) 2001;10(3):204-6.
58. Wara DW, Goldstein AL, Doyle NE, Ammann AJ. Thymosin activity in patients with cellular immunodeficiency. The New England Journal of Medicine 1975;292(2):70-4. [PUBMED: 1078552].
59. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term mortality and quality of life in sepsis: a systematic review. Critical Care Medicine 2010;38(5):1276-83. [PUBMED: 20308885].
60. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al.the Inflammation and Host Response to Injury Large-Scale Collaborative Research Program. A genomic storm in critically injured humans. The Journal of Experimental Medicine 2011;208(13):2581-90. [PUBMED: 22110166].
61. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al.Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. The New England Journal of Medicine 1991;324(7):429-36. [PUBMED: 1988827].